[go: up one dir, main page]

WO1999047102A3 - Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes - Google Patents

Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes Download PDF

Info

Publication number
WO1999047102A3
WO1999047102A3 PCT/US1999/006031 US9906031W WO9947102A3 WO 1999047102 A3 WO1999047102 A3 WO 1999047102A3 US 9906031 W US9906031 W US 9906031W WO 9947102 A3 WO9947102 A3 WO 9947102A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
presenting cells
methods
cells
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/006031
Other languages
English (en)
Other versions
WO1999047102A2 (fr
Inventor
Charles A Nicolette
Johanne Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to JP2000536343A priority Critical patent/JP2002506622A/ja
Priority to AU31023/99A priority patent/AU755156B2/en
Priority to EP99912710A priority patent/EP1063891A4/fr
Priority to CA002322750A priority patent/CA2322750A1/fr
Publication of WO1999047102A2 publication Critical patent/WO1999047102A2/fr
Publication of WO1999047102A3 publication Critical patent/WO1999047102A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des méthodes d'immunothérapie, destinées en particulier à induire une réponse immunitaire contre un antigène, chez un patient. Dans un aspect, cette invention concerne des cellules génétiquement modifiées présentatrices de l'antigène, qui constituent des présentatrices plus puissantes d'un peptide exogène que les cellules mères présentatrices de l'antigène. L'invention concerne également des compositions renfermant ces cellules génétiquement modifiées, ainsi qu'un excipient, par exemple un excipient pharmaceutiquement acceptable. Ces cellules génétiquement modifiées présentatrices de l'antigène peuvent notamment être utilisées en immunothérapie adoptive, ou pour accroître une population sensiblement pure de cellules immunitaires effectrices. L'invention concerne enfin des méthodes permettant accroître une population sensiblement pure de cellules.
PCT/US1999/006031 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes Ceased WO1999047102A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000536343A JP2002506622A (ja) 1998-03-20 1999-03-19 抗原提示細胞上での亢進した抗原提示の方法、およびそれにより産生する組成物
AU31023/99A AU755156B2 (en) 1998-03-20 1999-03-19 Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
EP99912710A EP1063891A4 (fr) 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes
CA002322750A CA2322750A1 (fr) 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7888098P 1998-03-20 1998-03-20
US60/078,880 1998-03-20

Publications (2)

Publication Number Publication Date
WO1999047102A2 WO1999047102A2 (fr) 1999-09-23
WO1999047102A3 true WO1999047102A3 (fr) 1999-10-21

Family

ID=22146768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006031 Ceased WO1999047102A2 (fr) 1998-03-20 1999-03-19 Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes

Country Status (5)

Country Link
EP (1) EP1063891A4 (fr)
JP (1) JP2002506622A (fr)
AU (1) AU755156B2 (fr)
CA (1) CA2322750A1 (fr)
WO (1) WO1999047102A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6144499A (en) * 1998-09-15 2000-04-03 University Of Pittsburgh In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression
EP1730263A4 (fr) * 2004-03-02 2008-01-23 Tsuneya Ohno Procedes et compositions ayant trait a des vaccins de cellules hybrides de traitement et prevention du cancer
PL1794327T3 (pl) 2004-09-14 2017-04-28 Argos Therapeutics, Inc. Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim
WO2009008713A1 (fr) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Inhibiteurs de tap à partir d'herpèsvirus 1 de primate d'europe et leur utilisation
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
US20170363629A1 (en) * 2014-11-05 2017-12-21 Board Of Regents, The University Of Texas System Biomarkers and targets for cancer immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5831068A (en) * 1995-08-21 1998-11-03 Duke University Method to increase the density of antigen on antigen presenting cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US5858376A (en) * 1993-11-30 1999-01-12 David C. Johnson HSV proteins for inhibiting recognition by cytotoxic T lymphocytes

Also Published As

Publication number Publication date
EP1063891A2 (fr) 2001-01-03
JP2002506622A (ja) 2002-03-05
AU755156B2 (en) 2002-12-05
EP1063891A4 (fr) 2002-10-23
AU3102399A (en) 1999-10-11
WO1999047102A2 (fr) 1999-09-23
CA2322750A1 (fr) 1999-09-23

Similar Documents

Publication Publication Date Title
AU6597998A (en) HLA-A2.1 binding peptides and their uses
AU5898400A (en) Hla binding peptides and their uses
WO2003040165A3 (fr) Peptides de liaison hla de classe i et ii et leurs utilisations
WO1995011008A3 (fr) Procedes et compositions de microencapsulation d'adjuvants
BR9708220A (pt) Peptìdios de ligação hla-a2.1 e seus usos
WO2001094944A3 (fr) Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
CA2330235A1 (fr) Complexe antigenique comprenant un peptide immunostimulateur, cd4 et un domaine de recepteur de chemokine pour traiter vih et des maladies immunitaires
WO1999042564A3 (fr) Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose
WO2003059276A3 (fr) Nouvelles cellules souches multipotentes d'origine mammalienne, methodes de preparation et methodes d'administration desdites cellules
WO2004027049A3 (fr) Procedes et compositions pour generer et controler le profil effecteur de lymphocytes t par le chargement et l'activation de sous-ensembles selectionnes de cellules presentant l'antigene
JP2003528887A5 (fr)
WO2003076603A3 (fr) Vesicules derivees de lymphocytes t, production et utilisations
AU5646101A (en) Immunotherapeutic methods and compositions
WO2006095330A3 (fr) Methodes et preparations de cellules immunogenes destinees a traiter des maladies associees a un antigene
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO1999047102A3 (fr) Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes
AU4791901A (en) Compositions and methods for dendritic cell-based immunotherapy
WO2004007528A3 (fr) Nouvelles compositions, et procedes d'elaboration de composes mhc de classe ii par echange de peptides
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
AU4577899A (en) Hla binding peptides and their uses
WO2001059073A3 (fr) Lymphocytes t cytotoxiques actives par des hybrides de cellules dendritiques
WO2004101737A3 (fr) Nouvel adjuvant capable d'activer de façon specifique la reponse immunitaire adaptative
HK1038754A1 (zh) 增加主要组织相容性复杂级别i限制抗原显示的成分及方法
WO2002044205A3 (fr) Peptides derives de ag85 de mycobacterie et utilisations associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 31023/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2322750

Country of ref document: CA

Ref country code: CA

Ref document number: 2322750

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09663073

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 536343

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999912710

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999912710

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999912710

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 31023/99

Country of ref document: AU